Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Johannes Gutenberg University Mainz · Cornell University · +20 more institutions
Abstract
Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma.
In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to receive bortezomib (1.3 mg per square meter of body-surface area) and dexamethasone (20 mg) alone (control group) or in combination with daratumumab (16 mg per kilogram of body weight) (daratumumab group). The primary end point was progression-free survival.
Citation impact
- FWCI
- 119.48
- Percentile
- 100%
- References
- 37
Authors
19- APAntonio PalumboCorresponding
Johannes Gutenberg University Mainz, Cornell University, University of Turin, University of Tübingen
- ACAsher Chanan‐Khan
Johannes Gutenberg University Mainz, Cornell University, Jacksonville College, WinnMed, Mayo Clinic in Florida, University of Tübingen
- KWKatja Weisel
Johannes Gutenberg University Mainz, Cornell University, Universitätsklinikum Tübingen, University of Tübingen
- AKAjay K. Nooka
Emory University, Johannes Gutenberg University Mainz, Cornell University, Cancer Institute (WIA), University of Tübingen
- TMTamás Masszi
Semmelweis University, Johannes Gutenberg University Mainz, Cornell University, University of Tübingen
Topics & keywords
- Daratumumab
- Medicine
- Internal medicine
- Multiple myeloma
- Bortezomib
- Dexamethasone
- Hazard ratio
- Oncology
- Good health and well-being